The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting
Authors' conclusion
MM780G is a cost-effective option for people with T1D managed in a Singapore setting.
Study context
- Population
- Simulated T1D individuals with baseline HbA1c of 8.4%; treatment effects from the ADAPT study; Singapore setting
- Participants
- 1,000 simulated individuals
- Comparison
- MM780G advanced hybrid closed-loop (AHCL) vs multiple daily injections (MDI) plus intermittently scanned continuous glucose monitor (isCGM)
- Outcome
- Incremental cost-effectiveness ratio per QALY gained, assessed at WTP thresholds of SGD 45,000 and SGD 114,165 per QALY
- Follow-up
- Lifetime
Methodological detailsIQVIA Core Diabetes Model (CDM) v9.5 simulation, lifetime horizon, Singapore health care payer perspective, 2023 costs, scenario analyses and probabilistic sensitivity analyses
- IQVIA Core Diabetes Model (CDM) v9.5 simulation
- Lifetime horizon
- Singapore health care payer perspective
- 2023 costs
- Scenario analyses and probabilistic sensitivity analyses
Main finding
Incremental cost-effectiveness ratio
Incremental cost-effectiveness ratio
SGD 33,797 (USD 24,850) per QALY gained
As reported in the abstract
- Life-years gained with MM780G
- +0.78
- Quality-adjusted life year (QALYs) gained with MM780G
- +1.45
- Cost savings through reduction in T1D complications
- Singapore Dollars (SGD) 25,465; USD 18,723
- Higher treatment costs with MM780G
- +SGD 74,538; +USD 54,805
Further findings
PSA probability of cost-effectiveness
- Probability at willingness-to-pay (WTP) SGD 45,000 per QALY
- 81%
- Probability at WTP SGD 114,165 per QALY
- 99%
- Findings were robust
Original publication
The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting. Diabetes Technol Ther. Published 22 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →